Hospital
Christus Health Northern Louisiana
Christus Health Northern Louisiana was paid $12.58M by Medicaid between Jan 2018 and Dec 2024, across 125 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoCHRISTUS HEALTH NORTHERN LOUISIANA
SHREVEPORT, LA 71105
SHREVEPORT, LA 71105
33aNPI1417950106assigned 05/27/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.58M
24GClaims379,372
24DCodes billed125
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#31 of 96
Median peer was paid$5.17M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,459 | $778K | |
| 2019 | 45,069 | $1.08M | |
| 2020 | 35,508 | $797K | |
| 2021 | 52,951 | $1.57M | |
| 2022 | 74,809 | $2.57M | |
| 2023 | 81,027 | $3.20M | |
| 2024incomplete | 55,549 | $2.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 29,317 | 26,699 | $4.28M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 39,342 | 36,519 | $3.12M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 4,310 | 3,917 | $657K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 1,170 | 1,076 | $503K |
| 71045 | Radiologic examination, chest; single view | 3.2% | 7,553 | 6,843 | $403K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.5% | 10,522 | 9,655 | $320K |
| 71046 | Radiologic examination, chest; 2 views | 2.4% | 3,851 | 3,525 | $304K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.3% | 31,703 | 12,793 | $289K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 3,983 | 3,723 | $228K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 9,416 | 8,130 | $206K |
| 80053 | Comprehensive metabolic panel | 1.6% | 28,326 | 24,597 | $198K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 38,843 | 32,594 | $194K |
113 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 2,641 | $144K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 3,985 | $134K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 3,980 | $134K |
| G0378 | Hospital observation service, per hour | 1.0% | 953 | $129K |
| 86003 | <1% | 1,441 | $95K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,699 | $83K |
| 81025 | <1% | 11,420 | $76K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,275 | $73K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,575 | $69K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,578 | $62K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 642 | $56K |
| 80050 | General health panel | <1% | 1,407 | $56K |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,186 | $55K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 921 | $53K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,621 | $52K |
| 81003 | <1% | 29,039 | $50K | |
| 80074 | <1% | 1,245 | $46K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,679 | $38K |
| 84484 | <1% | 4,325 | $34K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,393 | $33K |
| 87070 | <1% | 3,399 | $25K | |
| 83690 | <1% | 5,310 | $25K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 912 | $22K |
| 87081 | <1% | 3,758 | $21K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 416 | $17K |
| 83880 | <1% | 647 | $16K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,875 | $15K |
| 83655 | <1% | 1,192 | $14K | |
| 83735 | <1% | 3,333 | $14K | |
| 87077 | <1% | 1,727 | $14K | |
| 86738 | <1% | 1,365 | $13K | |
| 84439 | <1% | 1,464 | $13K | |
| 87420 | <1% | 1,066 | $11K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 469 | $11K |
| 82785 | <1% | 672 | $11K | |
| 45384 | <1% | 28 | $11K | |
| 86703 | <1% | 994 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,714 | $9K |
| 87186 | <1% | 1,040 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,131 | $7K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 306 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 907 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,424 | $6K |
| 83540 | <1% | 1,109 | $6K | |
| 86780 | <1% | 501 | $6K | |
| 97161 | <1% | 107 | $6K | |
| 59025 | Fetal non-stress test | <1% | 89 | $5K |
| 81001 | <1% | 1,897 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 104 | $5K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,831 | $4K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 140 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 569 | $3K |
| 86592 | <1% | 723 | $3K | |
| 80076 | <1% | 686 | $3K | |
| 83605 | <1% | 395 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 221 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 44 | $3K |
| 74018 | <1% | 54 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $2K |
| 97602 | <1% | 167 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 578 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 31 | $2K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 19 | $2K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 51 | $2K |
| 82550 | <1% | 487 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 41 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $2K |
| 85730 | <1% | 464 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 348 | $1K |
| 80069 | <1% | 297 | $1K | |
| 85610 | <1% | 517 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 220 | $1K |
| 82553 | <1% | 148 | $928.38 | |
| 97010 | <1% | 1,784 | $836.59 | |
| 72100 | <1% | 14 | $716.20 | |
| 80047 | <1% | 107 | $659.38 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 29 | $536.60 |
| 87205 | <1% | 102 | $463.09 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 40 | $432.85 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,103 | $377.94 |
| 81002 | <1% | 184 | $342.66 | |
| 94760 | <1% | 49 | $322.22 | |
| A6209 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 187 | $315.59 |
| 36591 | <1% | 215 | $260.92 | |
| 86328 | <1% | 23 | $232.22 | |
| 82728 | <1% | 55 | $204.87 | |
| 87147 | <1% | 46 | $202.45 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 60 | $196.33 |
| 87040 | <1% | 20 | $151.13 | |
| 96376 | <1% | 166 | $128.27 | |
| 83550 | <1% | 54 | $122.63 | |
| 97014 | <1% | 625 | $118.47 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 125 | $102.25 |
| 82465 | <1% | 27 | $95.72 | |
| 85379 | <1% | 17 | $92.23 | |
| 84478 | <1% | 14 | $83.07 | |
| 86308 | <1% | 14 | $81.61 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,246 | $70.38 |
| 11721 | <1% | 12 | $42.97 | |
| 81005 | <1% | 16 | $37.91 | |
| A6207 | Contact layer, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 74 | $28.64 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 60 | $19.08 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 87 | $12.66 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 25 | $12.66 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 35 | $5.10 |
| A6446 | Conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to three inches and less than five inches, per yard | <1% | 28 | $1.33 |
| A9270 | Non-covered item or service | 0% | 252 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 31 | $0.00 |
| J3490 | Unclassified drugs | 0% | 17 | $0.00 |
| 86318 | 0% | 35 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTRAWICK, THOMAS (CEO)
| Provider | Location | Paid |
|---|---|---|
| Christus Health Northern Louisiana | Shreveport, LA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.